Advertisement

Topics

Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 Pipeline Review, H2 2018 [Report Updated: 18092018] Prices from USD $3500

01:06 EDT 5 Oct 2018 | BioPortfolio Reports

Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 Pipeline Review, H2 2018


Summary


Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 Estrogen receptor beta ERB is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17betaestradiol or related ligands, the encoded protein forms homo or heterodimers that interact with specific DNA sequences to activate transcription.


Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 pipeline Target constitutes close to 21 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in PreRegistration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 2, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.


Report covers products from therapy areas Central Nervous System, Oncology, Metabolic Disorders, Women's Health, Male Health and Immunology which include indications Breast Cancer, Endometriosis, Multiple Sclerosis, Osteoporosis, Alzheimer's Disease, Hormone Sensitive Breast Cancer, Neuropathic Pain Neuralgia, Prostate Cancer, Benign Prostatic Hyperplasia, Bile Duct Cancer Cholangiocarcinoma, Carcinomas, Cognitive Impairment Associated With Schizophrenia CIAS, Colon Cancer, Demyelinating Diseases, Depression, Ductal Carcinoma In Situ, Fallopian Tube Cancer, Inflammation, Male Hypogonadism, Malignant Pleural Mesothelioma, Neuromyelitis Optica Devic's Syndrome, Obesity, Ovarian Cancer, Peritoneal Cancer and Vasomotor Symptoms of Menopause Hot Flashes.


The latest report Estrogen Receptor Beta Pipeline Review, H2 2018, outlays comprehensive information on the Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2

The report reviews Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 targeted therapeutics and enlists all their major and minor projects

The report assesses Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 Pipeline Review, H2 2018 [Report Updated: 18092018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Estrogen Receptor Beta ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2 Pipeline Review, H2 2018 [Report Updated: 18092018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...